- Home
- CDT vs BDRX Comparison
CDT vs BDRX Comparison
Compare CDT & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- BDRX
- Stock Information
- Founded
- CDT 2019
- BDRX 2000
- Country
- CDT United States
- BDRX United Kingdom
- Employees
- CDT N/A
- BDRX N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- CDT Health Care
- BDRX Health Care
- Exchange
- CDT Nasdaq
- BDRX Nasdaq
- Market Cap
- CDT 4.2M
- BDRX 4.6M
- IPO Year
- CDT N/A
- BDRX N/A
- Fundamental
- Price
- CDT $2.84
- BDRX $6.33
- Analyst Decision
- CDT
- BDRX
- Analyst Count
- CDT 0
- BDRX 0
- Target Price
- CDT N/A
- BDRX N/A
- AVG Volume (30 Days)
- CDT 655.2K
- BDRX 375.2K
- Earning Date
- CDT 11-14-2025
- BDRX 09-12-2025
- Dividend Yield
- CDT N/A
- BDRX N/A
- EPS Growth
- CDT N/A
- BDRX N/A
- EPS
- CDT N/A
- BDRX N/A
- Revenue
- CDT N/A
- BDRX N/A
- Revenue This Year
- CDT N/A
- BDRX N/A
- Revenue Next Year
- CDT N/A
- BDRX N/A
- P/E Ratio
- CDT N/A
- BDRX N/A
- Revenue Growth
- CDT N/A
- BDRX N/A
- 52 Week Low
- CDT $2.72
- BDRX $5.00
- 52 Week High
- CDT $2,198.40
- BDRX $92.00
- Technical
- Relative Strength Index (RSI)
- CDT 57.41
- BDRX 44.21
- Support Level
- CDT $2.78
- BDRX $5.71
- Resistance Level
- CDT $3.22
- BDRX $7.84
- Average True Range (ATR)
- CDT 0.38
- BDRX 0.66
- MACD
- CDT -0.07
- BDRX -0.25
- Stochastic Oscillator
- CDT 6.74
- BDRX 21.09
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.